Congestive Processes Of The Pelvic Organs (Prostatostasis), Erectile Dysfunction, Sexual Function
Conditions
Keywords
Ginseng, Prostatostasis, Erectile Dysfunction
Brief summary
The purpose of this study is to investigate the efficacy of Phytotherapy Raylis (Ginseng Root Powder 50 mg, False Ginseng Root Powder 50 mg, Codonopsis Root Powder 50 mg, Astragalus Membranaceus Root Powder 50 mg, Epimedium Alpinum Herbal Extract 100 mg) In Congestive Processes Of The Pelvic Organs (Prostatostasis) In Congestive Processes Of The Pelvic Organs (Prostatostasis)
Interventions
DRUGRaylis
Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)
OTHERstandard prostatostasis therapy
Sponsors
The Clinic of Men's Health and Couple Longevity, Russia
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Age 20-60 years * Symptoms of prostatostasis lasting for at least 3 months during the past 6 months: * Pathological changes on uroflowmetry (maximum flow rate of less than 15 ml / s, average urinary flow rate of less than 12 ml / sec) * TRUS Prostate volume more than 22 ml at TRUS * TRUS picture of Prostatostasis * I-PSS 7-20 * IIEF-5) - 12-21
Exclusion criteria
* Contraindications and limitations to use of the drug Raylis listed in the instructions for medical use \* * Diabetes mellitus (type 1 and type 2, decompensation) * Neurogenic disorders (acute cerebral circulatory disorders, Alzheimer's disease, spinal cord injury) * A history of pelvic trauma * Patients who had undergone radical prostatectomy and other surgical interventions on the pelvic organs * Concomitant use of supplements to improve the erectile function, use of the anti-androgens, anti-depressants, finasteride. * Diagnosed BPH * Current participation in a clinical trial and / or study medication for 30 days prior to inclusion * Any form of substance abuse, mental disorder or condition which, in the opinion of the investigator, may complicate communication with the researcher. * The inability or unwillingness to comply with the scheme of visits according to protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TRUS prostate | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Uroflowmetry | 3 months |
Other
| Measure | Time frame |
|---|---|
| IPSS | 3 months |
Countries
Russia
Contacts
Primary ContactYuliya Tishova, MD PhD
Outcome results
None listed